Teva Pharmaceutical Industries Limited (TEVA)
Overview
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-11-05 |
| Earnings Call | 2025-11-05 |
| Avg EPS Estimate | 0.7076 |
| Low EPS Estimate | 0.64 |
| High EPS Estimate | 0.7482 |
| Revenue | |
| Avg Revenue Forecast | 4,463,666,670 |
| Low Revenue Forecast | 4,328,000,000 |
| High Revenue Forecast | 4,561,000,000 |
TEVA Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $2,160,999,936 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0.483 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 1.064 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $17,542,000,640 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
TEVA Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $4,521,999,872 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $1,390,000,000 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $1,603,500,032 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 49.60% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 21.41% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | -0.94% | Net profit margin, which reflects overall profitability. |
TEVA Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 256.69% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $17,542,000,640 | Used together with cash and EBITDA to assess debt-paying ability. |
TEVA Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 0.30% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for TEVA (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $24.6 | Latest stock trading price |
| Price Target (High) | $30 | Analyst highest expected price |
| Price Target (Low) | $21.08 | Analyst lowest expected price |
| Price Target (Average) | $24.9 | Average target price across analysts |
| Price Target (Median) | $25 | Median of target prices |
| Average Rating Score | 1.36 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | strong_buy | Consensus rating |
| Analyst Coverage Count | 9 | Number of analysts providing estimates |
| Cash Holdings | $2,160,999,936 | Total cash held by the company |
| Cash per Share | $1.88 | Cash value per outstanding share |
| Total Debt | $17,542,000,640 | Company's total debt |
| Quick Ratio | 0.483 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 1.064 | Overall short-term liquidity |
| Debt/Equity Ratio | 256.69% | Leverage ratio: Debt / Equity |
| EBITDA | $4,521,999,872 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $16,627,999,744 | Total company revenue |
| Revenue per Share | $14.612 | Total revenue divided by shares outstanding |
| Gross Profit | 49.60% | Revenue minus cost of goods sold |
| Return on Assets | 5.37% | Net income / Total assets |
| Return on Equity | -2.42% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 0.30% | Year-over-year revenue growth |
| Gross Margin | 49.60% | Gross profit / Total revenue |
| EBITDA Margin | 27.20% | EBITDA / Revenue |
| Operating Margin | 21.41% | Operating income / Revenue |
| Profit Margin | -0.94% | Net income / Revenue |
| Free Cash Flow | $1,603,500,032 | Cash left after capital expenditures |
| Operating Cash Flow | $1,390,000,000 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |